Metabolic Tumor Volume Measured by ¹⁸F-FDG PET/CT is Associated with the Survival of Unresectable Hepatocellular Carcinoma Treated with PD-1/PD-L1 Inhibitors Plus Molecular Targeted Agents

References

• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi:10.1016/S0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label Phase 2 trial. Lancet Oncol. 2018;19(7):940–952. doi:10.1016/S1470-2045(18)30351-6
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. New Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–2970. doi:10.1200/JCO.20.00808
   PubMed Web of Science ®Google Scholar
• Chen B, Lei J, Zhao H, et al. Efficacy and safety of TKI plus PD-1 inhibitors in elderly uHCC patients: a retrospective study. J Hepatocell Carcinoma. 2022;9:1171–1185. doi:10.2147/JHC.S387254
   PubMed Web of Science ®Google Scholar
• Wu JY, Yin ZY, Bai YN, et al. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study. J Hepatocell Carcinoma. 2021;8:1233–1240. doi:10.2147/JHC.S332420
   PubMed Web of Science ®Google Scholar
• D’Alessio A, Rimassa L, Cortellini A, Pinato DJ. PD-1 blockade for hepatocellular carcinoma: current research and future prospects. J Hepatocell Carcinoma. 2021;8:887–897. doi:10.2147/JHC.S284440
   PubMed Web of Science ®Google Scholar
• Ziogas IA, Evangeliou AP, Giannis D, et al. The role of immunotherapy in hepatocellular carcinoma: a systematic review and pooled analysis of 2402 patients. Oncologist. 2021;26(6):e1036–e1049. doi:10.1002/onco.13638
   PubMed Web of Science ®Google Scholar
• Chen S, Huang Z, Jia W, et al. Association of the pretreatment lung immune prognostic index with survival outcomes in advanced hepatocellular carcinoma patients treated with PD-1 inhibitors. J Hepatocell Carcinoma. 2020;7:289–299. doi:10.2147/JHC.S277453
   PubMed Web of Science ®Google Scholar
• Yang X, Hu Y, Yang K, et al. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers. J Immunother Cancer. 2021;9(5):e001942. doi:10.1136/jitc-2020-001942
   PubMed Web of Science ®Google Scholar
• Li N, Ren SH, Qin YF, et al. Four-pyroptosis gene-based nomogram as a novel strategy for predicting the effect of immunotherapy in hepatocellular carcinoma. Biomed Res Int. 2022;2022:2680110. doi:10.1155/2022/2680110
   PubMed Web of Science ®Google Scholar
• Nan Z, Guoqing W, Xiaoxu Y, et al. The predictive efficacy of Tumor Mutation Burden (TMB) on nonsmall cell lung cancer treated by immune checkpoint inhibitors: a systematic review and meta-analysis. Biomed Res Int. 2021;2021:1780860. doi:10.1155/2021/1780860
   PubMed Web of Science ®Google Scholar
• Yamashige D, Kawamura Y, Kobayashi M, et al. Potential and clinical significance of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for evaluating liver cancer response to lenvatinib treatment. Oncology. 2021;99(3):169–176. doi:10.1159/000510754
   PubMed Web of Science ®Google Scholar
• Lee SM, Kim HS, Lee S, Lee JW. Emerging role of (18) F-fluorodeoxyglucosepositron emission tomography for guiding management of hepatocellular carcinoma. World J Gastroenterol. 2019;25(11):1289–1306. doi:10.3748/wjg.v25.i11.1289
   PubMed Web of Science ®Google Scholar
• Wang G, Zhang W, Chen J, et al. Pretreatment metabolic parameters measured by (18) F-FDGPET to predict the pathological treatment response of HCC patients treated with PD-1 inhibitors and lenvatinib as a conversion therapy in BCLC stage C. Front Oncol. 2022;12:884372. doi:10.3389/fonc.2022.884372
   PubMed Web of Science ®Google Scholar
• Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology. 2012;264(2):559–566. doi:10.1148/radiol.12111148
   PubMed Web of Science ®Google Scholar
• Lim R, Eaton A, Lee NY, et al. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med. 2012;53(10):1506–1513. doi:10.2967/jnumed.111.101402
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition). Liver Cancer. 2018;7(3):235–260. doi:10.1159/000488035
   PubMed Web of Science ®Google Scholar
• Huo L, Li N, Wu H, et al. Performance evaluation of a new high-sensitivity time-of-flight clinical PET/CT system. EJNMMI Phys. 2018;5(1):29. doi:10.1186/s40658-018-0229-4
   PubMedGoogle Scholar
• Davison J, Mercier G, Russo G, Subramaniam RM. PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma. AJR Am J Roentgenol. 2013;200(3):635–640. doi:10.2214/AJR.12.9138
   PubMed Web of Science ®Google Scholar
• Boellaard R, O’Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181–200. doi:10.1007/s00259-009-1297-4
   PubMed Web of Science ®Google Scholar
• Hwang SH, Lee JW, Cho HJ, Kim KS, Choi GH, Yun M. Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with very early and early hepatocellular carcinoma. Clin Nucl Med. 2017;42(1):34–39. doi:10.1097/RLU.0000000000001449
   PubMed Web of Science ®Google Scholar
• Castello A, Rimassa L, Personeni N, Pressiani T, Smiroldo V, Lopci E. Metabolic switch in hepatocellular carcinoma patients treated with sorafenib: a proof-of-concept trial. Mol Imaging Biol. 2020;22(5):1446–1454. doi:10.1007/s11307-020-01489-6
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Rohren EM, Abdel-Wahab R, et al. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. Eur J Nucl Med Mol Imaging. 2017;44(6):969–978. doi:10.1007/s00259-016-3583-2
   PubMed Web of Science ®Google Scholar
• Ito K, Schöder H, Teng R, et al. Prognostic value of baseline metabolic tumor volume measured on (18) F-fluorodeoxyglucosepositron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy. Eur J Nucl Med Mol Imaging. 2019;46(4):930–939. doi:10.1007/s00259-018-4211-0
   PubMed Web of Science ®Google Scholar
• Seban RD, Mezquita L, Berenbaum A, et al. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging. 2020;47(5):1147–1157. doi:10.1007/s00259-019-04615-x
   PubMed Web of Science ®Google Scholar
• Larimer BM, Wehrenberg-Klee E, Dubois F, et al. Granzyme B PET imaging as a predictive biomarker of immunotherapy response. Cancer Res. 2017;77(9):2318–2327. doi:10.1158/0008-5472.CAN-16-3346
   PubMed Web of Science ®Google Scholar
• Hurkmans DP, Basak EA, Schepers N, et al. Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer. J Immunother Cancer. 2020;8(1):e000586. doi:10.1136/jitc-2020-000586
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Lee PC, Chao Y, Chen MH, et al. Predictors of response and survival in immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. Cancers. 2020;12(1). doi:10.3390/cancers12010182
   Web of Science ®Google Scholar
• Choi WM, Lee D, Shim JH, et al. Effectiveness and safety of nivolumab in child-pugh B patients with hepatocellular carcinoma: a real-world cohort study. Cancers. 2020;12(7):1968. doi:10.3390/cancers12071968
   PubMed Web of Science ®Google Scholar
• Kuo HY, Chiang NJ, Chuang CH, et al. Impact of immune checkpoint inhibitors with or without a combination of tyrosine kinase inhibitors on organ-specific efficacy and macrovascular invasion in advanced hepatocellular carcinoma. Oncol Res Treat. 2020;43(5):211–220. doi:10.1159/000505933
   PubMed Web of Science ®Google Scholar
• Harding JJ, Abu-Zeinah G, Chou JF, et al. Frequency, morbidity, and mortality of bone metastases in advanced hepatocellular carcinoma. J Natl Compr Canc Netw. 2018;16(1):50–58. doi:10.6004/jnccn.2017.7024
   PubMed Web of Science ®Google Scholar
• Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003;44(2):213–221.
   PubMed Web of Science ®Google Scholar
• Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med. 1995;36(10):1811–1817.
   PubMed Web of Science ®Google Scholar